A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Molecular-Guided Therapy for Childhood Cancer
Phase NA Completed
186 enrolled 12 charts
PREFER
Completed
1,429 enrolled
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Phase 1 Completed
7 enrolled
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Phase 2 Completed
5 enrolled
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Phase 1 Completed
24 enrolled
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Phase 1 Completed
62 enrolled
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Phase NA Completed
44 enrolled
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Phase 1 Completed
14 enrolled
Aflac ST0901
Phase 1 Completed
18 enrolled
AflacST1402
Phase 1 Completed
13 enrolled
Trial of Dasatinib in Advanced Sarcomas
Phase 2 Completed
366 enrolled 16 charts
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Phase 1/2 Completed
78 enrolled 11 charts
Tabectedin to Treat Children and Adolescents With Cancer
Phase 1 Completed
12 enrolled
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Phase 2 Completed
40 enrolled 11 charts
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
132 enrolled
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
Phase 1/2 Completed
91 enrolled
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
64 enrolled
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
Phase 1 Completed
10 enrolled
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Phase 1/2 Completed
40 enrolled